DF
MRNA icon

Donoghue Forlines’s Moderna MRNA Stock Holding History

Donoghue Forlines’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,382
Closed -$626K – 268
2022
Q2 		$626K Sell
4,382
-689
-14% -$98.5K 0.16% 166
2022
Q1 		$874K Buy
+5,071
New +$854K 0.19% 171
2021
Q4 		– Sell
-2,101
Closed -$809K – 286
2021
Q3 		$809K Buy
2,101
+219
+12% +$80.8K 0.16% 150
2021
Q2 		$442K Sell
1,882
-5,065
-73% -$905K 0.08% 186
2021
Q1 		$910K Sell
6,947
-8,299
-54% -$1.2M 0.18% 137
2020
Q4 		$1.59M Buy
+15,246
New +$1.54M 0.31% 62
2020
Q3 		– Sell
-21,795
Closed -$1.4M – 131
2020
Q2 		$1.4M Buy
+21,795
New +$1.19M 0.37% 52

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Donoghue Forlines's MRNA Position: Q3 2022 in Review

Donoghue Forlines sold out of Moderna (MRNA) in Q3 2022, closing a stake of 4,382 shares — an estimated $626K sold.

Donoghue Forlines first reported a position in MRNA in Q2 2020 and held it in 7 quarters. The position peaked at $1.59M in Q4 2020. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Donoghue Forlines reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Donoghue Forlines sold 4,382 Moderna shares in Q3 2022, an estimated $626K.
  • Donoghue Forlines first reported a position in Moderna in Q2 2020 and held it in 7 quarters.
  • Donoghue Forlines's Moderna position peaked at $1.59M in Q4 2020.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Donoghue Forlines's 13F filing for Q3 2022, filed 7 Nov 2022.